Abbott a top pick by RBC

RBC Capital Markets analyst Phil Nalbone reiterated Abbott Laboratories a top pick with average risk and $55 price target after the company reported positive data from the Spirits II clinical study of the Xience drug-eluting stent. The change in vascular diameter showed Xience was superior on the primary endpoint. A statistically significant reduction in percent diameter stenosis and binary restenosis was also seen for Xience versus Taxus, according to the analyst. Shares of the Abbott Park, Ill.-based biopharmaceutical company were down 2 cents, or 0.04%, at $48.35 on volume of 4,763.700 shares versus the three-month running average of 5,043,450 shares. (NYSE: ABT)

CryoCath reiterated at outperform

CryoCath Technologies Inc. was reiterated at outperform, speculative risk, and C$7 price target by RBC Capital Markets analyst Phil Nalbone after the company received conditional approval to begin enrolling patients into the STOP AF pivotal U.S. trial. Initially, 75 patients will be enrolled at five centers, according to the analyst. Shares of the Montreal-based medical device company were up C$0.14 cents, or 6.48%, at C$2.30, on volume of 189,590 shares versus the three-month running average of 47,472 shares. (Toronto: CYT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.